01:55 PM EDT, 08/06/2024 (MT Newswires) -- Cadrenal Therapeutics ( CVKD ) said Tuesday it is in talks with Abbott Laboratories ( ABT ) about its planned pivotal study of oral anticoagulant tecarfarin in patients with recently implanted left ventricular assist device, or LVAD.

Abbott manufactures the HeartMate 3 LVAD.

Cadrenal said tecarfarin was granted orphan drug designation by the US Food and Drug Administration to prevent blood clots and strokes in patients with LVAD and other implanted cardiac devices.